ContractChange in Control and Severance Agreement • March 10th, 2016 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • California
[DATE] [NAME] [ADDRESS] Re: Amended and Restated Change in Control and Severance Agreement Dear [NAME]: You and OncoMed Pharmaceuticals, Inc. (the “Company”) are parties to a Change in Control and Severance Agreement dated [_____________] (the “Change in Control Agreement”), which sets forth, among other things, the terms and conditions of certain severance benefits payable to you in the event of a qualifying termination of your employment. This letter (this “Agreement”) amends and restates the Change in Control Agreement to provide you with additional benefits in the event of certain terminations of your employment. This Agreement supersedes the Change in Control Agreement and any other agreement or policy to which the Company is a party with respect to the cessation of your employment with the Company. 1. Definitions. For purposes of the Agreement, the following terms shall have their respective meanings set forth below: (a) “Cause” shall mean any of the following: (i) your intention
AMENDMENT 3 TO THE COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • March 10th, 2016 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment 3 to the Collaboration and Option Agreement (the “Amendment”) is made and entered into on November 4, 2015 (the “Amendment Date”), by and between OncoMed Pharmaceuticals, Inc., a Delaware corporation located at 800 Chesapeake Drive, Redwood City, California 94063, United States of America (“OncoMed”), and Bayer Pharma AG, a German corporation located at Müllerstrasse 178, 13353 Berlin, Germany which previously acted under the name Bayer Schering Pharma AG (“BSP”). OncoMed and BSP are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
